Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | fructose-1,6-bisphosphatase | 0.0633 | 1 | 1 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0018 | 0 | 0.5 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0018 | 0 | 0.5 |
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.0633 | 1 | 1 |
Echinococcus multilocularis | fructose 1,6 bisphosphatase 1 | 0.0633 | 1 | 1 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0018 | 0 | 0.5 |
Trypanosoma brucei | sedoheptulose-1,7-bisphosphatase | 0.0235 | 0.3532 | 0.3532 |
Toxoplasma gondii | fructose-bisphospatase I | 0.0235 | 0.3532 | 0.3532 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0018 | 0 | 0.5 |
Toxoplasma gondii | sedoheptulose-1,7-bisphosphatase | 0.0235 | 0.3532 | 0.3532 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0018 | 0 | 0.5 |
Loa Loa (eye worm) | fructose-1,6-bisphosphatase | 0.0633 | 1 | 1 |
Echinococcus granulosus | fructose 16 bisphosphatase 1 | 0.0633 | 1 | 1 |
Schistosoma mansoni | fructose-16-bisphosphatase-related | 0.0633 | 1 | 1 |
Trypanosoma cruzi | sedoheptulose-1,7-bisphosphatase, putative | 0.0235 | 0.3532 | 0.3532 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0018 | 0 | 0.5 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0018 | 0 | 0.5 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0018 | 0 | 0.5 |
Leishmania major | 0.0633 | 1 | 1 | |
Toxoplasma gondii | fructose-bisphospatase II | 0.0633 | 1 | 1 |
Trypanosoma cruzi | sedoheptulose-1,7-bisphosphatase, putative | 0.0235 | 0.3532 | 0.3532 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0018 | 0 | 0.5 |
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.0633 | 1 | 1 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0018 | 0 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.